Skip to Content

Bristol-Myers Squibb Co - Stock Quote BMY

Rating as of

Morningstar's Bristol-Myers Squibb Co Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Bristol Faces Major Near-Term Patent Losses, but New Drugs Should Help Stabilize the Top Line

Karen Andersen, CFA Sector Strategist

Business Strategy and Outlook

| Damien Conover, CFA |

Adept at partnerships and acquisitions, Bristol-Myers Squibb has built a strong portfolio of drugs and a robust pipeline. This strategy is seen with its large acquisition of Celgene, which netted the firm an excellent pipeline and a strong entrenchment in blood cancer. We believe the strong overall pipeline helps support its wide moat.

Unlock Our Full Analysis With Morningstar Investor

Bristol-Myers Squibb Co's Company Profile

Business Description

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

430 East 29th Street, 14th Floor
New York, NY, 10016
T +1 212 546-4000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 32,200

Bristol-Myers Squibb Co's Related News